Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Chianchinon Aug 03, 2021 1:48am
112 Views
Post# 33641133

RE:RE:RE:RE:Expectations for Q2

RE:RE:RE:RE:Expectations for Q2...8 Years of low expectations and counting. GUD is still overpriced at $5 with a PE of 10 it would have to earn $.50 per shares. It would take GUD another 8 Years to get there if big IF. Simply look at GILD is had had a PE of 10 for the last five Years but because of not much growth is has gone nowhere with the share price. Old renamed drugs does not provide exponential growth like newly discovered with huge block buster growth sales like Moderna. On the other hand, Pfizer with 50% the same vaccine has only gone up about 15% because Pfizer too does not have huge potential growth in the pipeline. In all GUD was, is and will be a losing money investment Dud. Run and  fast if you would like to leave some inheritance for the grand kids. Eight Years of losing says it all about these promoting paid influencers dudes with multiple alias. They do not own a single share of GUD   
<< Previous
Bullboard Posts
Next >>